SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Uniting the six native Japanese dog breeds. Kendu is the keeper of peace, the preserver of life, and the protector of unity. Join the pack!!

Kendu

KENDU is trending due to community excitement around its real-world brand initiatives, including energy drinks, merchandise, and sponsored events, fostering strong community engagement and IRL presence. The community is actively discussing these initiatives, along with the project's expansion and potential for significant growth, expressing strong conviction and encouraging others to join. Discussions also include updates on holder counts and on-chain metrics, alongside continued building efforts.

Concordium is the Layer-1 blockchain built for a new era of digital trust. With mandatory, privacy-preserving identity verification built into its consensus layer, utilizing zero-knowledge proof technology. Concordium also enables Protocol-level tokens that eliminate smart contract risks by being issued directly at the consensus layer, with built-in features that provide the infrastructure for compliance-ready use cases. At its core is Smart Money - programmable, identity-embedded, and compliance-ready value that powers trusted interactions across Web3. Smart Money enables frictionless exchange, automation, and verifiable trust by design. Unlike conventional blockchains, Concordium integrates trust, accountability, and privacy into its architecture from the ground up  bridging traditional systems and Web3 to build a transparent, sustainable digital future. The name Concordium comes from the Latin concordia—meaning harmony and agreement—a reflection of its mission to build infrastructure that embeds trust, privacy, and compliance into every interaction.

Concordium

Concordium ($CCD) is trending as community members highlight its focus on privacy, compliance, and real-world utility, positioning it as a key infrastructure play for stablecoins and PayFi. Recent partnerships, including integration with bitcoin.com wallets, are also sparking increased interest and bullish sentiment. The community believes its unique approach to verifiable trust and on-chain identity is setting it up for significant growth.

Litecoin is a peer-to-peer cryptocurrency created by Charlie Lee. It was created based on the Bitcoin protocol but differs in terms of the hashing algorithm used. Litecoin uses the memory intensive Scrypt proof of work mining algorithm. Scrypt allows consumer-grade hardware such as GPU to mine those coins.  Why Litecoin? Litecoin is a cryptocurrency that has evolved from Bitcoin after its own popularity in the industry, this alternative, or ‘altcoin’ has emerged to allow investors to diversify their digital currency package, according to Investopedia. Litecoin is one of the most prominent altcoins and was created by former Google employee and Director of Engineering at Coinbase, Charlie Lee. Litecoin was the first to alter Bitcoin and the most significant difference is that it takes 2.5 minutes for Litecoin to generate a block, or transaction, in comparison to Bitcoin's 10 minutes.  ‘While this matters little to traders, miners who use hardware to run Bitcoin's network cannot switch over to Litecoin. This keeps bigger mining conglomerates away from Litecoin because they cannot easily optimize their profits by swapping to another coin, contributing to a more decentralized experience. Litecoin also has bigger blocks, and more coins in circulation, making it more affordable and swift when transacting,’ Investopedia explained.  As explained above, Litecoin can transact a lot faster than Bitcoin, but there are also a number of other characteristics that investors need to know before trading. Litecoin can handle higher volumes of transactions because of the capability of transacting faster and if Bitcoin attempted to transact on the scale of its altcoin, a code update would be needed. However, Litecoin’s blocks would be larger, but with more ‘orphaned blocks'. The faster block time of litecoin reduces the risk of double spending attacks - this is theoretical in the case of both networks having the same hashing power.  Litecoin Technical Details: The transaction confirmation time taken for Litecoin is about 2.5 minutes on average (as compared to Bitcoin's 10 minutes). The Litecoin network is scheduled to cap at 84 million currency units.   Litecoin has inspired many other popular alternative currencies (eg. Dogecoin) because of its Scrypt hashing algorithm in order to prevent ASIC miners from mining those coins. However it is said that by the end of this year, Scrypt ASIC will enter the mass market.

Litecoin

Litecoin is trending with community members highlighting a recent price pump, while others suggest it's a bull trap. Discussions include potential breakouts, comparisons to other cryptocurrencies, and speculation about future price targets. Some community members point to Litecoin's fundamentals and adoption as reasons for optimism.

Internet Computer (IC) is the world’s first blockchain that is capable of running at web speed at unrestrictive capacities. Built by the DFINITY Foundation, IC aims to recreate the web by supporting smart contract development at scale and changing the way people can interact using web services. Internet Computer aims to extend the public internet, so that it can be the world’s computing platform, in a decentralized manner. Internet Computer sets to revolutionalize the design of the crypto economy, with an aim to overhaul traditional software services.   The project was founded in October 2016 by Dominic WIllams and have raised a total of $121 million from investors such as Adreessen Horowitz, Polychain Capital, Multicoin Capital and such. On May 10, 2021, DFINITY launched the Internet Computer into the public domain, marking it a major milestone for ICP as it means the internet now functions as a decentralised global computer. This is marked by the release of all of the Internet Computer’s source code into the public domain, as well as ICP utility token that allows tens of thousands of community members to govern the Internet Computer network.  ICP is Internet Computer's native token. It plays three prominent roles:  1. Network Governance: Users that participate in the governance will be rewarded with ICPI 2. Production of Cycles for Compute: ICP can be converted into cycles where it is used as the transaction fee to access the network. Cycles are burned after used. 3. Rewarding Users: ICP is used as the rewards to incentivize users to participate in the network such as securing the network.

Internet Computer

Internet Computer (ICP) is trending as traders discuss its recent price surge and potential pullback, with many viewing dips as buying opportunities. The community is actively debating price targets, with some expecting a significant run, possibly fueled by developments in AI integration and its potential as a decentralized cloud platform. Some are comparing it to previous altcoin pumps, while others believe in its long-term potential.

ADMA Biologics, Inc. operates as a biopharmaceutical company, which is engaged in manufacturing, marketing, and developing specialty plasma-derived biologics. The firm operates through the following business segments: ADMA BioManufacturing, Plasma Collection Center, and Corporate. The ADMA BioManufacturing segment consists of immune globulin manufacturing and development operations. The Plasma Collection Center consists of source plasma collection facilities. The Corporate segment includes general and administrative overhead expenses. The company was founded by Adam S. Grossman and Jerrold B. Grossman on June 24, 2004 and is headquartered in Ramsey, NJ.

Adma Biologics Inc

ADMA Biologics is trending as investors assess its current valuation following earnings, with community members debating future growth potential and buyback strategies. Despite strong fundamentals and a reiterated revenue outlook, some express frustration with the stock's recent performance and discuss potential catalysts. Bullish sentiment persists among long-term holders who anticipate a substantial price increase, while others speculate about a possible takeover.

Aerodrome Finance is a next-generation AMM designed to serve as Base's central liquidity hub, combining a powerful liquidity incentive engine, vote-lock governance model, and friendly user experience. Aerodrome inherits the latest features from Velodrome V2.

Aerodrome Finance

Aerodrome Finance is trending as the community focuses on its position as the primary DEX on Coinbase's Base network, with discussions around future integrations and revenue potential driving bullish sentiment. Many believe that the integration positions AERO to reach new all-time highs. Some users are drawing comparisons to Binance's BNB token, speculating on a similar trajectory for AERO.

monday.com Ltd. engages in the business of operating a cloud-based visual work operating system that consists of modular building blocks that can be easily used and assembled to create software applications and work management tools and serves as a connective layer to integrate with various digital tools across an organization. It operates through the following geographical segments: United States, EMEA, United Kingdom, and Rest of the World. The company was founded by Roy Mann, Eran Kampf, and Eran Zinman in 2012 and is headquartered in Tel Aviv, Israel.

Monday.Com Ltd

Monday.com Ltd

Monday.com is trending due to a significant sell-off following earnings, despite the company beating expectations; the community is actively debating whether this drop is an overreaction or a sign of deeper issues. Community members are also discussing the impact of AI on the company's future, as well as a recent analyst downgrade. Despite the negative sentiment, some investors view the dip as a buying opportunity, citing the company's strong fundamentals and growth potential.

UNI is the governance token for Uniswap, an Automated Market Marker DEX on the Ethereum blockchain. The UNI token allows token holders to participate in the governance of the protocol. Key decisions such as usage of the treasury or future upgrades can be decided through a governance vote.

UniSwap

Uniswap ($UNI) is trending as the community discusses its potential for growth, driven by high annualized fees and strong fundamentals. The recent launch of the Ethereum Protocol Advocacy Alliance, aimed at shaping crypto regulation, is also sparking interest. Traders are closely watching for breakout opportunities and fee-sharing developments.

Avalanche is a high throughput smart contract blockchain platform. Validators secure the network through a proof-of-stake consensus protocol. It is said to be fast, low cost, and environmental friendly.

Avalanche

Avalanche is trending as the community discusses its potential, driven by buzz around tokenization and real-world asset (RWA) applications. Some traders are eyeing key resistance levels, while others speculate on the impact of potential treasury-related news and partnerships. Despite recent volatility, there's a sense of optimism about AVAX's long-term prospects within the broader crypto market.

GigaCloud Technology, Inc. specializes in global end-to-end business-to-business (B2B) electronic commerce (e-commerce) for large parcel merchandise. Its B2B ecommerce platform, the “GigaCloud Marketplace” integrates everything from discovery, payments and logistics tools into one easy-to-use platform. The firm offers a comprehensive solution that transports products from the manufacturers warehouse to the end customers doorstep, all in one place. The company was founded by Lei Wu on August 29, 2006 and is headquartered in El Monte, CA.

GigaCloud Technology Inc - Ordinary Shares - Class A

GigaCloud Technology Inc

GigaCloud Technology is trending as investors discuss its low P/E ratio and potential growth, despite concerns about tariffs and a recent settlement. Community members are debating the company's legitimacy and future prospects, with some highlighting its strong revenue and potential for a short squeeze. Overall, discussions revolve around whether GCT is undervalued or facing significant headwinds.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Biogen's Q2 Earnings & Sales Beat, 2025 Outlook Raised, Stock Up

BIIB posts Q2 earnings and sales beat, lifts 2025 outlook on new drug growth and displays resilient MS performance.

Sage Therapeutics, Inc. (SAGE) Reports Q2 Loss, Beats Revenue Estimates

Sage Therapeutics (SAGE) delivered earnings and revenue surprises of +17.71% and +80.91%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Biogen Gears Up to Report Q2 Earnings: Here's What to Expect

Biogen's Q2 results may show MS drug declines partially offset by gains from newer drugs.

What Makes Sage Therapeutics (SAGE) a New Buy Stock

Sage Therapeutics (SAGE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

JPMorgan cut its price target on Sage Therapeutics to $8.5 from $11 based on the recently announced buyout by Supernus Pharmaceuticals, representing an 8.5% downside from the last close.The research firm maintained a 'Neutral' rating on the stock.Last week, Supernus said it would acquire Sage for $8.5 per share in cash, plus a contingent value right (CVR) worth up to $3.5, based on commercial milestones for Zurzuvae, an FDA-approved treatment for postpartum depression co-developed with Biogen.&nbsp;The total transaction value of up to $12 per share reflects a 79% premium to Sage’s last closing price before the announcement.The deal, expected to close in the third quarter of 2025, is intended to expand Supernus’ neuropsychiatry portfolio and&nbsp;could reduce annual costs by up to&nbsp;$200 million.The company also guaranteed a cash payout at closing, excluding value from the CVR, which remains contingent on future sales performance.&nbsp;Several other firms adjusted their price targets in response to the Supernus deal: Piper Sandler lowered its target to $8.50 from $9,&nbsp;while Truist raised its target to $9 from $8&nbsp;and Canaccord increased its target to $8.50 from $8, each maintaining a ‘Hold’ or ‘Neutral’ rating.&nbsp;BofA removed its rating altogether, stating that Sage shares are no longer trading on fundamentals following the acquisition announcement.H.C. Wainwright noted the $22.4 million breakup fee may not be large enough to prevent a competing offer, particularly from Biogen, which already co-commercializes Zurzuvae with Sage in the U.S.In January, Sage Therapeutics’ board&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/biib-stock-gains-onfda-nod-for-leqembi-dosing/chblEfgRYE">unanimously rejected</a> Biogen's unsolicited offer to acquire all outstanding shares for $7.22 per share.&nbsp;The company said the offer “significantly undervalued” Sage and was not in the best interest of shareholders.On Stocktwits, retail sentiment was ‘bullish’ amid ‘high’ message volume.Shares of Sage Therapeutics closed up 1.9% at $9.3 on Friday. The stock has risen 60.9% so far in 2025.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Sage Therapeutics logo of a biopharmaceutical company seen on a smartphone and on a pc screen. (Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images)

Sage Therapeutics Stock: JPMorgan Sees 8% Downside After Supernus Buyout Terms

Analysts have also noted that the relatively low breakup fee may leave room for a competing offer, possibly from Biogen.

Equity

Supernus Pharmaceuticals, Inc. (SUPN) on Monday announced its intent to <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.supernus.com/news-releases/news-release-details/supernus-pharmaceuticals-acquire-sage-therapeutics-strengthening">acquire</a> Sage Therapeutics, Inc. (SAGE) for up to $795 million. SAGE stock traded 34% higher on Monday morning following the announcement.Under the terms of the deal, Supernus intends to acquire Sage for a total consideration of $12 per share in cash, including $8.50 per share payable at closing and a contingent value right (CVR) worth up to $3.50 per share in cash. The CVR is payable upon achieving certain net sales and commercial milestones, the companies said.The total consideration represents a premium of about 79% from SAGE’s closing price of $6.7 on Friday.The transaction is expected to close in the third quarter of 2025 and strengthen Supernus’ neuropsychiatry portfolio with the addition of Zurzuvae, the only oral medicine approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with postpartum depression.Zurzuvae was co-developed by Sage and Biogen, Inc. (BIIB). Through a collaboration agreement with Biogen, Supernus will report collaboration revenue that is 50% of the total net revenue Biogen records for Zurzuvae in the U.S.In 2024 alone, Sage recorded a collaboration revenue of $36.1 million from net sales of Zurzuvae.Jack Khattar, President and CEO of Supernus Pharmaceuticals, said the acquisition augments the company’s growth profile by adding a fourth growth product to its portfolio, in addition to Qelbree, Onapgo, and Gocovri.The acquisition is also expected to be significantly accretive in 2026, with cost synergies of up to $200 million on an annual basis, the companies said.On Stocktwits, retail sentiment around SUPN jumped from ‘neutral’ to ‘bullish territory over the past 24 hours, while chatter increased from ‘normal’ to ‘high’ levels.<figure class="image"><img style="aspect-ratio:625/68;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_16_at_10_18_03_AM_png_8f57b78080.webp" alt="Screenshot 2025-06-16 at 10.18.03 AM.png" width="625" height="68"><figcaption>SUPN's Sentiment Meter and Message Volume as of 10:15 a.m. ET on June 16, 2025 | Source: Stocktwits</figcaption></figure>Meanwhile, sentiment around SAGE increased from ‘neutral’ to ‘extremely bullish’ territory while message volume increased from ‘normal’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:628/67;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_16_at_10_24_57_AM_png_4d871e71b4.webp" alt="Screenshot 2025-06-16 at 10.24.57 AM.png" width="628" height="67"><figcaption>SAGE's Sentiment Meter and Message Volume as of 10:20 a.m. ET on June 16, 2025 | Source: Stocktwits</figcaption></figure>This year, <a href="https://stocktwits.com/symbol/SAGE">SAGE stock</a> has risen 56% while <a href="https://stocktwits.com/symbol/SUPN">SUPN stock</a> fell about 10%.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/trump-organization-enters-telecom-market-touts-us-made-phone/chlntPmRRR8">Trump Organization Enters Telecom Market, Touts US-Made Phone Amid President’s Push To Reshore Smartphone Production</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Supernus Pharmaceuticals Gets Retail Excited Over $795M Acquisition Plan For Sage Therapeutics

Under the terms of the deal, Supernus is looking to acquire Sage for a total consideration of $12 per share in cash.

Why Is Sage Therapeutics (SAGE) Down 11.1% Since Last Earnings Report?

Sage Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on Tuesday, February 11, 2025

Sage Therapeutics, Inc. (NASDAQ: SAGE), today announced that it will host a live webcast on Tuesday, February 11, 2025 at 4:30 p.m. ET to review fourth quarter and full year 2024 financial results...

Biogen Inc. shares climbed 1.7% on Monday afternoon, reaching a nearly two-week high, as positive regulatory news countered fallout from a rejected acquisition proposal.Sage Therapeutics announced its board had unanimously rejected Biogen's unsolicited Jan. 10&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/sage-stock-soars-on-biogen-bid/chGN0nXRNV">offer</a> to acquire all outstanding Sage shares for $7.22 per share.&nbsp;The small-cap biotech firm called the proposal "significantly undervaluing" the company and added that it was not in the best interest of its shareholders.Sage's board also revealed plans to explore strategic alternatives, cautioning that a transaction is not guaranteed.&nbsp;Meanwhile, Sage reaffirmed its commitment to establishing Zurzuvae as the standard treatment for postpartum depression.&nbsp;Biogen, which co-markets Zurzuvae, had argued that full ownership would aid its rollout but expressed little interest in Sage's broader pipeline when it placed its bid.<figure class="image"><img style="aspect-ratio:1318/324;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/BIIB_sentiment_and_message_volume_Jan_27_d1b89b799f.png" alt="BIIB sentiment and message volume Jan 27.png" width="1318" height="324"><figcaption>BIIB sentiment and message volume Jan 27 as of 1:20 pm ET | source: Stocktwits</figcaption></figure>Following the rejection, retail sentiment for Biogen turned 'bearish' on Stocktwits, with increased message volume reflecting investor concerns about the deal's implications.<stembedurl>https://stocktwits.com/Gito/message/601644664</stembedurl><stembedurl>https://stocktwits.com/Scanners_Free/message/601610361</stembedurl>However, Biogen received a significant boost as the FDA on Sunday approved a supplemental biologics license application for Leqembi, developed in collaboration with Eisai Co. Ltd.&nbsp;The new label allows for once-every-four-weeks intravenous maintenance dosing following an 18-month initiation phase of biweekly treatments.Leqembi, used to treat early-stage Alzheimer's disease, addresses patients with mild cognitive impairment or mild dementia.&nbsp;The updated dosing regimen is expected to improve patient compliance while enhancing convenience.However, Biogen's challenges remain stark; the stock has lost nearly 40% over the past 12 months.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration the logo of Biogen is seen on a smartphone with the FDA logo in the background. (Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images)  

Biogen Rises On FDA Nod for Alzheimer's Drug Dosing Regimen, But Sage Deal Fallout Irks Retail

The small-cap biotech firm called the proposal "significantly undervaluing" the company and added that it was not in the best interest of its shareholders.

Sage Therapeutics Board of Directors Initiates Review of Strategic Alternatives and Rejects Biogens Unsolicited Acquisition Proposal

Sage Therapeutics, Inc. (Nasdaq: SAGE) (Sage or the Company), today announced that its Board of Directors has initiated a process to explore strategic alternatives for the Company. The Board intends...

SAGE Therapeutics, Inc. is a biopharmaceutical company, which engages in providing solutions to brain health medicines. It focuses on diseases and disorders of the brain. Its products include ZURZUVAE and ZULRESSO. The company was founded by Steven Marc Paul and Douglas Covey on April 16, 2010 and is headquartered in Cambridge, MA.

Sage Therapeutics Inc

$ASTS

$RKLB

$BBAI

$NBIS

Which earnings release are you most excited for the week of Nov. 10? 
 
Drop a comment for others.

Current Price	$8.68
Prev Close	$8.70
Open	$8.74
Dividend Yield	0.00%
50-Day Moving Average	$8.44
Beta	1.07
Avg. Volume	3.55M
PE Ratio	-1.77

52-Week High	$9.36
52-Week Low	$4.62
Market Capitalization	$544.97M
EPS (Annual)	-$6.59
Price to Book	1.47
Revenue Per Employee	$116,835.69
Enterprise Value/EBITDA	N/A

SAGE
Sage Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest SAGE News

SAGESage Therapeutics Inc